Evidence map›Paper›PMID 40855291›Full record

ArticleJournal of nanobiotechnology2025

Ultrasound-actuated platelet mimetic nanomotors enable targeted piezocatalytic ROS storm for precision thrombolysis.

Ye Zhao, Jinchen He, Yuxi Liu, Hassna Soummane, Pan Ran, Qian Yang, Xiaofang Gao, Wenxiong Cao, Long Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ye Zhao *Sichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, School of Bioscience and Technology, Chengdu Medical College, Chengdu, 610500, P. R. China.
Jinchen He *Sichuan Clinical Research Center for Radiation and Therapy, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu Medical College, No.4, North Section 4, Second Ring Road, Chengdu, 610051, P. R. China.
Yuxi Liu *Sichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, School of Bioscience and Technology, Chengdu Medical College, Chengdu, 610500, P. R. China.
Hassna SoummaneMohammed VI University Hospital, Cadi Ayyad University, Marrakech, Morocco.
Pan RanSichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, School of Bioscience and Technology, Chengdu Medical College, Chengdu, 610500, P. R. China.
Qian YangSichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, School of Bioscience and Technology, Chengdu Medical College, Chengdu, 610500, P. R. China.
Xiaofang GaoSichuan Clinical Research Center for Radiation and Therapy, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu Medical College, No.4, North Section 4, Second Ring Road, Chengdu, 610051, P. R. China. Gaoxiaofang_gxf@163.com.
Wenxiong CaoKey Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, P. R. China. 996838@hainanu.edu.cn.
Long ZhaoSichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, School of Bioscience and Technology, Chengdu Medical College, Chengdu, 610500, P. R. China. longzhao@cmc.edu.cn.

Funding

the Health Commission of Sichuan Province Medical Science and Technology Program 24CXTD09the Nuclear Medicine Science and Technology Innovation of China Nuclear Medicine ZHYLZD2025012the Open Project of Sichuan Clinical Research Center for Radiation and Therapy 2024ZX03the Scientific Research Foundation of Science & Technology Department of Sichuan Province 2024NSFSC1972
6 · The paper itself

Abstract

Thrombotic diseases pose life-threatening risks, yet current thrombolytic therapies face limitations including poor targeting and bleeding risks. To address this, ultrasound-activatable nanomotors (hBT-Pt@Pm) were developed through the integration of hollow BaTiO₃/Pt Schottky heterojunctions with platelet membrane (Pm) coatings. The hollow structure enhances piezocatalytic efficiency by shortening charge migration distances, while Pt deposition improves carrier separation, collectively boosting reactive oxygen species (ROS) generation under ultrasound. Finite element simulations confirmed a 5.8-fold increase in piezoelectric potential compared to solid BaTiO₃. Asymmetric Pt caps enable cavitation-driven thrombus penetration, and Pt-mediated H₂O₂ decomposition generates O₂ bubbles to amplify ROS production. In vitro, Pm coating conferred 5.2-fold higher thrombus accumulation than non-targeted nanoparticles. In murine venous thrombosis models, the nanomotors achieved near-complete clot dissolution via synergistic piezocatalysis and mechanical penetration, without systemic toxicity. This approach provides a targeted, ultrasound-powered alternative to conventional thrombolytics, combining precision therapy with inherent biosafety.

Indexed as

Biomimetic MaterialsBlood PlateletsNanoparticlesReactive Oxygen SpeciesThrombolytic TherapyAnimalsCatalysisDisease Models, AnimalHumansMicePlatinumThrombosisUltrasonic WavesVenous ThrombosisPlatinumReactive Oxygen SpeciesH2O2-responsivenessPanomotor penetrationPiezocatalysis therapySchottky heterojunctionTarget thrombolysis

Identifiers

PMID40855291
PMCPMC12376482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.